drugset / Trial / NCT06611345
A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers
Recruiting
60 enrolled
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
AstraZeneca · collab
NaSingle-groupOpen-labelTreatment
Summary
Unresectable BTC represents an area of unmet medical need due to its very aggressive nature, limited treatment options, and poor prognosis. This study is to evaluate the efficacy and safety of adding TTF to the established regimen of durvalumab plus GemCis for the treatment of patients with previously untreated, unresectable BTC.
Timeline
- Start
- 2024-10-21
- Primary completion
- 2026-10-30
- Completion
- 2027-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |